Loading...
•
Jun 30, 2022
Aura Biosciences Q2 2022 Earnings Report
Reported financial results and provided clinical development and operational highlights.
Key Takeaways
Aura Biosciences reported second quarter financial results, highlighting the progress in advancing belzupacap sarotalocan's clinical development, including plans to dose the first patient in the Phase 1 trial for NMIBC in Q3 2022 and initiate a pivotal trial in early-stage choroidal melanoma in Q4 2022.
On track to dose the first patient in the Phase 1 study evaluating Belzupacap Sarotalocan (AU-011) for the treatment of Non-Muscle Invasive Bladder Cancer in Q3 2022.
On track to initiate pivotal trial in early-stage choroidal melanoma in Q4 2022.
FDA granted Fast Track designation for belzupacap sarotalocan for the treatment of NMIBC.
Aura plans to file an IND for choroidal metastases in Q4 of 2022.
Forward Guidance
Aura believes its current cash and cash equivalents and marketable securities are sufficient to fund its operations into 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...